SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-182544
Filing Date
2024-07-23
Accepted
2024-07-23 06:04:01
Documents
13
Period of Report
2024-07-23
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d864314d8k.htm   iXBRL 8-K 23431
  Complete submission text file 0001193125-24-182544.txt   149382

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fdmt-20240723.xsd EX-101.SCH 2899
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fdmt-20240723_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fdmt-20240723_pre.xml EX-101.PRE 11740
15 EXTRACTED XBRL INSTANCE DOCUMENT d864314d8k_htm.xml XML 3771
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

IRS No.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39782 | Film No.: 241132836
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)